Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMGCoA) reductase

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Leuenberger, Tina ^a,b   Pfueller, Caspar F ^c   Luessi, Felix ^a   Bendix, Ivo ^d   Paterka, Magdalena ^a,b   Prozorovski, Timour ^e   Treue, Denise ^c   Luenstedt, Sarah ^b   Herz, Josephine ^d   Siffrin, Volker ^a,b   Infante Duarte, Carmen ^c   Zipp, Frauke ^a,b   Waiczies, Sonia ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; PYRROLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOLECULAR DYNAMICS; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; PHAGOCYTOSIS; REGULATORY T LYMPHOCYTE;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; PYRROLES; T-LYMPHOCYTES, REGULATORY;

EID: 84904259303     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100871     Document Type: Article

References (50)

1. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, et al. (1989) Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169: 1169-1178. (Pubitemid 19085847)
2. De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, et al. (1996) Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184: 1413-1424. (Pubitemid 26354697)
3. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, et al. (2000) The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 191: 927-936.
4. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7: 19-30. (Pubitemid 46020824)
5. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222.
6. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627-1638. (Pubitemid 36026474)
7. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779. (Pubitemid 32983013)
8. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193: 233-238. (Pubitemid 32524454)
9. Legge KL, Gregg RK, Maldonado-Lopez R, Li L, Caprio JC, et al. (2002) On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 196: 217-227. (Pubitemid 34787511)
10. Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, et al. (2004) HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172: 85-93. (Pubitemid 38058605)
11. Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, et al. (2006) Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 79: 529-538. (Pubitemid 44831230)
12. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197: 725-733. (Pubitemid 36350867)
13. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84. (Pubitemid 35291443)
14. Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, et al. (2005) Atorvastatin Induces T Cell Anergy via Phosphorylation of ERK1. J Immunol 174: 5630-5635. (Pubitemid 40593204)
15. Waiczies S, Bendix I, Prozorovski T, Ratner M, Nazarenko I, et al. (2007) Geranylgeranylation but not GTP loading determines rho migratory function in T cells. J Immunol 179: 6024-6032.
16. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, et al. (2002) Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 32: 2237-2245. (Pubitemid 34965886)
17. Benvenuti F, Hugues S, Walmsley M, Ruf S, Fetler L, et al. (2004) Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science 305: 1150-1153. (Pubitemid 39100327)
18. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203: 401-412. (Pubitemid 43290849)
19. Burns S, Hardy SJ, Buddle J, Yong KL, Jones GE, et al. (2004) Maturation of DC is associated with changes in motile characteristics and adherence. Cell Motil Cytoskeleton 57: 118-132. (Pubitemid 38134052)
20. Akbari O, DeKruyff RH, Umetsu DT (2001) Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2: 725-731. (Pubitemid 32747162)
21. D'Amico A, Wu L (2003) The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med 198: 293-303. (Pubitemid 36987854)
22. Zhang Y, Mukaida N, Wang J, Harada A, Akiyama M, et al. (1997) Induction of dendritic cell differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor, and tumor necrosis factor alpha in vitro from lineage phenotypes-negative c-kit+ murine hematopoietic progenitor cells. Blood 90: 4842-4853. (Pubitemid 28007198)
23. Zhang Y, Zhang YY, Ogata M, Chen P, Harada A, et al. (1999) Transforming growth factor-beta1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway. Blood 93: 1208-1220. (Pubitemid 29076135)
24. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402. (Pubitemid 32001026)
25. Johansson SM, Admyre C, Scheynius A, Gabrielsson S (2008) Different types of in vitro generated human monocyte-derived dendritic cells release exosomes with distinct phenotypes. Immunology 123: 491-499. (Pubitemid 351280963)
26. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, et al. (2005) Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 174: 6440-6448. (Pubitemid 40663838)
27. Admyre C, Johansson SM, Qazi KR, Filen JJ, Lahesmaa R, et al. (2007) Exosomes with immune modulatory features are present in human breast milk. J Immunol 179: 1969-1978.
28. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. (Pubitemid 28155090)
29. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, et al. (2003) CD40 ligation releases immature dendritic cells from the control of regulatory CD4+ CD25+ T cells. Immunity 19: 877-889. (Pubitemid 37542307)
30. Yates SF, Paterson AM, Nolan KF, Cobbold SP, Saunders NJ, et al. (2007) Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol 179: 967-976.
31. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH (1997) Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159: 4772-4780. (Pubitemid 127471012)
32. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, et al. (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 93: 2499-2504. (Pubitemid 26104798)
33. Laman JD, de Smet BJ, Schoneveld A, van Meurs M (1997) CD40-CD40L interactions in atherosclerosis. Immunol Today 18: 272-277. (Pubitemid 27261445)
34. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN (2007) Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 82: 1365-1374. (Pubitemid 350276946)
35. Scheffold A, Murphy KM, Hofer T (2007) Competition for cytokines: T(reg) cells take all. Nat Immunol 8: 1285-1287. (Pubitemid 350131165)
36. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, et al. (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet
37. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607-1608. (Pubitemid 38625664)
38. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71: 1390-1395.
39. Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dorr J, et al. (2008) Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 3: e1928.
40. Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, et al. (2010) Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsingΓÇöremitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Multiple Sclerosis 16: 450-454.
41. Sorensen PS, Lycke J, Er+ñlinna JP, Edland A, Wu X, et al. (2011) Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. The Lancet Neurology 10: 691-701.
42. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, et al. (2010) Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Multiple Sclerosis 16: 848-854.
43. Kamm CP, El Koussy M, Humpert S, Findling O, Burren Y, et al. (2014) Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial. PLoS ONE 9: e86663.
44. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, et al. (2009) Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72: 1989-1993.
45. Weber M, Prod'homme T, Youssef S, Dunn S, Steinman L, et al. (2014) Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. Journal of Neuroinflammation 11: 29.
46. Li XL, Liu Y, Cao LL, Li H, Yue LT, et al. (2013) Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines. Mol Cell Neurosci 56: 85-95.
47. Xu H, Li XL, Yue LT, Li H, Zhang M, et al. (2014) Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells and NKRP1(+) cells. J Neuroimmunol 269: 28-37.
48. Bird PI, Trapani JA, Villadangos JA (2009) Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol 9: 871-882.
49. Ames BN, Shigenaga MK, Hagen TM (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 90: 7915-7922. (Pubitemid 23260825)
50. Hugues S (2010) Dynamics of dendritic cell-T cell interactions: a role in T cell outcome. Semin Immunopathol 32: 227-238.